InhaleRx secures A$38.5m deal to accelerate pain and mental health breakthroughs

By on    Pharma Industry News  

InhaleRx secures A$38.5m deal to accelerate pain and mental health breakthroughs

Melbourne-based healthcare innovator InhaleRx Limited (ASX: IRX) has secured a substantial funding deal worth up to AUD 38.5 million, aiming to revolutionize the treatment of pain management and mental health disorders. The deal, inked with Clendon Biotech Capital, is set to fund the clinical development of two of InhaleRx’s breakthrough drug-device products, IRX-211 and IRX-616a, […]

Novus Therapeutics begins phase 1 trial of OP0201 in otitis media

By on    Pharma Industry News  

Novus Therapeutics begins phase 1 trial of OP0201 in otitis media

Novus Therapeutics has launched a phase 1 pharmacodynamics clinical trial for its promising candidate, OP0201, aimed at treating otitis media—a common middle ear infection. The California-based specialty pharmaceutical company, known for its focus on ENT (ear, nose, and throat) disorders, has begun dosing the first adult patients in the trial, named OP0201-C-001, which is taking […]